Datopotamab deruxtecan-dlnk is approved as initial systemic therapy for unresectable/metastatic TNBC when PD-1/PD-L1 inhibitors are not appropriate, in patients ...
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple ...
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus ...
CHICAGO -- Treatment with investigational izalontamab brengitecan (iza-bren) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable locally ...
The treatment paradigm of stage II to III triple-negative breast cancer (TNBC) is rapidly evolving, with the recent incorporation of pembrolizumab to neoadjuvant chemotherapy improving disease ...
Coupled with TNBC's aggressive biology, high rate of early recurrence, and tendency to metastasize to vital organs like the brain and lungs, long-term outcomes were historically poor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results